Cargando…
非小细胞肺癌中microRNAs与EGFR-TKIs继发性耐药机制的研究进展
In recent years, in non-small cell lung cancer (NSCLC) targeted therapy, especially in patients with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKI) more and more come into the clinical treatment, but EGFR-TKI resistance not only influence the drug sensitivit...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000411/ https://www.ncbi.nlm.nih.gov/pubmed/25539612 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.12.07 |